Hemispherx stock: buy or sell?
September 6th, 2019
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
Should I buy Hemispherx stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Hemispherx BioPharma stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Hemispherx BioPharma stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we found 1 rating published for HEB stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
Hemispherx stock analysis
Hemispherx BioPharma skyrocketed an extraordinary 4.26% and closed at $1.96.
Shares of Hemispherx ended on Sep 6th at $1.96 and skyrocketed an extraordinary 4.26%. From a daily perspective, HEB is in a short term uptrend after plotting its last bottom ($1.78, on August/29) higher than the previous bottom, and its last top ($2.11, on Sep/5) also over the previous top. Now trading in between its last bottom and last top HEB might consolidate in a plain range, waiting to break out over $2.11 or down under $1.78.
After sliding a spooky -7.22% in a week late August, Hemispherx BioPharma closed this week at $1.96 and skyrocketed an outstanding 8.89%.
Since price and 20-weeks moving average lines crossed down by mid February, HEB fell $-8.16 per share (-80.63%).
Hemispherx stock price history
Hemispherx IPO was on August 19th, 1996 at $1,914.00 per share1. Since then, HEB stock declined a -99.90%, with a yearly average of -4.30%.
1: Adjusted price after possible price splits or reverse-splits.
Hemispherx stock historical price chart
HEB stock reached 52-week highs on April at $14.96, and all-time highs 2000-03-02 with a price of 10032.
Hemispherx stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price prediction for Hemispherx stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter posting its last earnings report on April, Hemispherx . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Hemispherx BioPharma annual sales plunged a bloodcurdling -16.02% to $0.37 M USD from $0.44 marked in 2017. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) plummed a -783.91% to -2,673.84%.
|2012||$0.21 M||-||$-17.35 M-8145.5%||-|
|2013||$0.15 M||-29.58%||$-16.23 M-10820.0%||-6.46%|
|2014||$0.20 M||31.33%||$-17.45 M-8857.9%||7.52%|
|2015||$0.13 M||-32.49%||$-15.23 M-11451.1%||-12.72%|
|2016||$0.09 M||-30.83%||$-7.50 M-8154.3%||-50.74%|
|2017||$0.44 M||375.00%||$-8.26 M-1889.9%||10.09%|
|2018||$0.37 M||-16.02%||$-9.81 M-2673.8%||18.82%|
Quarterly financial resultsHemispherx BioPharma posted $0.24 million in sales for 2018-Q4, a 531.58% improvement compared to previous quarter. Reported quarter earnings marked $-1.61 M with a profit margin of -669.58%. Profit margin rocketed a 7,430.42% compared to previous quarter when profit margin was -8,100.00%. When comparing turnover to same quarter last year, Hemispherx sales marked an astounding growth and climbed a 380.00%. Looking back to recent quarterly results, Hemispherx posted 2 negative quarters in a row.
|2017-Q1||$0.08 M||-||$-2.82 M-3357.1%||-|
|2017-Q2||$0.21 M||153.57%||$-2.19 M-1028.2%||-22.34%|
|2017-Q3||$0.09 M||-57.75%||$-1.25 M-1391.1%||-42.83%|
|2017-Q4||$0.05 M||-44.44%||$-1.99 M-3986.0%||59.19%|
|2018-Q1||$0.06 M||12.00%||$-2.71 M-4844.6%||36.13%|
|2018-Q2||$0.03 M||-41.07%||$-2.42 M-7318.2%||-10.98%|
|2018-Q3||$0.04 M||15.15%||$-3.08 M-8100.0%||27.45%|
|2018-Q4||$0.24 M||531.58%||$-1.61 M-669.6%||-47.79%|
Hemispherx ownershipWhen you are planning to buy a company, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Hemispherx BioPharma, 12.78% of all outstanding shares are owned by its staff.
In case of Hemispherx stock, 6.09% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for HEB stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Hemispherx BioPharma:
|Market cap||$0.5 M|
|Total shares||0.3 M|
|Float shares||2.0 M|
|- Institutional holdings (%)||6.1%|
|- Insider holdings (%)||12.8%|
|Shares in short selling||0.0%|
|Friday, September 6th, 2019|
|Day range||$1.90 - $2.06|
|Average true range||$0.19|
|50d mov avg||$2.77|
|100d mov avg||$4.33|
|200d mov avg||$6.48|
Hemispherx performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Hemispherx against in the following table: